## **ForPatients**

by Roche

Neoangiogenesis Age-Related Macular Degeneration

## Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (STAIRWAY)

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT03038880 CR39521

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

## Trial Summary:

This was a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in treatment-naive participants with neovascular age related macular degeneration (nAMD). Only one eye was chosen as the study eye.

Hoffmann-La Roche Sponsor		Phase 2 Phase		
NCT03038880 CR39521 Trial Identifiers				
Eligibility Criteria:				
Gender All	Age >= 50 Years		Healthy Volunteers	